Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418 (Q27641873)

1

0 references

Yafeng Xue

2

0 references

Stefan Berg

3

0 references

Sven Hellberg

4

0 references

Mats Ormö

5

0 references

Yvonne Nilsson

6

0 references

Ann-Cathrin Radesäter

7

0 references

Eva Jerning

8

0 references

Per-Olof Markgren

9

0 references

Thomas Borgegård

10

0 references

Martin Nylöf

11

0 references

Alfredo Giménez-Cassina

12

0 references

Félix Hernández

13

0 references

Jose J Lucas

14

0 references

Javier Díaz-Nido

15

0 references

Jesús Avila

Journal of Biological Chemistry

16

0 references

language of work or name

English

0 references

publication date

14 November 2003

0 references

published in

0 references

volume

278

0 references

page(s)

45937-45

0 references

issue

46

0 references

cites work

Mechanisms of neuronal degeneration in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Tau aggregation into fibrillar polymers: taupathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Neurodegenerative tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Immunocytochemistry of tau phosphoserine 413 and tau protein kinase I in Alzheimer pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

A68: a major subunit of paired helical filaments and derivatized forms of normal Tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains beta-catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Direct association of presenilin-1 with beta-catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Lithium and synaptic plasticity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Specificity and mechanism of action of some commonly used protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

A molecular mechanism for the effect of lithium on development

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Tau is essential to beta -amyloid-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

21 January 2018

The renaissance of GSK3

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

NGF increases neuritic complexity of cholinergic interneurons in organotypic cultures of neonatal rat striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Effects of the 3-hydroxyanthranilic acid analogue NCR-631 on anoxia-, IL-1 beta- and LPS-induced hippocampal pyramidal cell loss in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

PROCHECK: a program to check the stereochemical quality of protein structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M306268200

21 January 2018

Identifiers

DOI

10.1074/JBC.M306268200

1 reference

Consolidated OpenCitations Corpus – April 2017

205306

205306

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference